Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO

Recruiting now · Not applicable

Conditions studied: Extracorporeal Membrane Oxygenation Complication

In brief

The purpose of this study is to evaluate the effectiveness and safety of nafamostat mesilate compared with unfractionated heparin for anticoagulation in patients with ECMO after cardiac surgery.

Key facts

Study ID

NCT06276010

Run by

Xiaotong Hou

People needed

80

Starts

2024-07-01

Expected to finish

2026-12-31

Last updated by the study team

2025-09-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years old
• VA-ECMO or VV-ECMO was accepted after cardiac surgery.
• The ECMO treatment team believes that systemic anticoagulation is needed
• Sign the informed consent form

You may not qualify if…

• The researchers believe that there are other causes of active bleeding that are not suitable to participate in this study.
• Long-term use of anticoagulants before establishment of ECMO
• Antiplatelet drugs were used before the establishment of ECMO
• Severe liver insufficiency
• Connective tissue disease
• There is a history of allergy to heparin or nemolastat mesylate.
• Pregnant
• Previous diagnosis of heparin-induced thrombocytopenia
• Expect to die within 48 hours
• ECPR

Where it is running

• Beijing Anzhen Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.